Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cognitive impairment in depression and Alzheimer's disease: differential diagnosis and approaches to therapy

https://doi.org/10.14412/2074-2711-2019-3-116-123

Full Text:

Abstract

Mild to moderate cognitive impairment (CI) in elderly and senile age may be caused by various neuropsychiatric diseases, including Alzheimer's disease (AD) and depression. The literature review presents the mechanisms of CI development in AD and depressive disorders, as well as their course, prognosis, and differential diagnosis. Mild and moderate depressions in AD, their clinical variants, course and treatment approaches are described. Treatment for CI is shown to focus on therapy of the underlying disease, in which the former occurs. Antidepressants are used to treat depression and depressive disorders in AD, by taking into account the efficacy and tolerability of the drugs at old age.

About the Authors

N. A. Tyuvina
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Psychiatry and Narcology, 

11, Rossolimo St., Build. 9, Moscow 119021



S. V. Prokhorova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Psychiatry and Narcology, 

11, Rossolimo St., Build. 9, Moscow 119021



T. N. Maksimova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Psychiatry and Narcology, 

11, Rossolimo St., Build. 9, Moscow 119021



M. S. Verbitskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Psychiatry and Narcology, 

11, Rossolimo St., Build. 9, Moscow 119021



References

1. Tyuvina NA, Balabanova VV. Dementia of the Alzheimer type: current state of the problem. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1):61-7. (In Russ.). doi: 10.14412/2074-2711-2014-1-61-67

2. Gavrilova SI. Is mild cognitive decline the pre-clinical stage of Alzheimer's? Consilium Medicum. 2004;(2):153-7. (In Russ.).

3. Zakharov VV, Yakhno NN. Moderate cognitive impairment syndrome in the elderly: diagnosis and treatment. Russkii meditsinskii zhurnal. 2004;(10):573-8. (In Russ.).

4. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter. Early detection of dementia: mild cognitive impairment (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8;56(9):1133-42.

5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington,: Am. Psychiatr.Pub; 2013.

6. Tyuvina NA, Balabanova VV. Treatment for Alzheimer's diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):80-5. (In Russ.). doi: 10.14412/2074-2711-2015-3-80-85

7. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii: rukovodstvo dlya vrachei [Dementias. A guide for doctors]. Moscow: MEDpress-inform; 2010. 264 p.

8. Korostelev VI. Features of pathogenesis, clinic and course of involutional and endogenous depression. Issues of diagnosis of mental and neurological disorders. Vestnik Baltiiskogo federal'nogo universiteta im. I. Kanta. 2016;(2):33—9. (In Russ.).

9. Zakharov VV, Yakhno NN. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste: metodicheskoe posobie dlya vrachei [Cognitive disorders in the elderly and senile age. Methodical manual for doctors]. Moscow; 2005. 71 p.

10. MKB-10. Mezhdunarodnaya statisticheskaya klassifikatsiya boleznei i problem, svyazannykh so zdorov'em, 10 peresmotr. Zheneva, VOZ [ICD-10. International statistical classification of diseases and health problems, 10 revision. Geneva, WHO]. Moscow: Meditsina; 1995. Volume 1. P. 315, 317, 320, 510-511.

11. Damulin IV. Bolezn' Al'tsgeimera i sosudistaya dementsiya [Alzheimer's disease and vascular dementia]. Yakhno NN, editor. Moscow: Meditsina; 2002. 85 p.

12. Damulin IV, Yakhno NN. Degenerative diseases with cognitive disorders. In: Yakhno NN, editor. Bolezni nervnoi sistemy [Diseases of the nervous system]. Volume 2. Moscow: Meditsina; 2005. P. 189-207.

13. Hendrie HC. Epidemiology of dementia and Alzheimer`s disease. Am J Geriatr Psychiatry 1998 Spring;6(2 Suppl 1):S3-18.

14. Zakharov VV. All-Russian program of research of epidemiology and therapy of cognitive disorders in old age («Prometheus»). Nevrologicheskii zhurnal. 2006;(11):27-32. (In Russ.).

15. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736 (15)60461-5. Epub 2015 Mar 12.

16. Naumenko AA, Gromova DO, Trofimova NV, Preobrazhenskaya IS. Alzheimer’s disease: diagnosis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):91–7. (In Russ.). doi: 10.14412/2074-2711-2016-4-91-97

17. Zakharov VV, Vakhnina NV, Gromova DO, Tarapovskaya AA. Review of the proceedings of the International conference on Alzheimer’s disease. Washington, USA, July 18–23, 2015. Nevrologicheskii zhurnal. 2015;20(6):65-9. (In Russ.).

18. Kolykhalov IV. Modern approaches to optimization of Alzheimer's disease therapy. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2016; (6):87-92. (In Russ.).

19. Hammar A, Ardal G. Cognitive functioning in major depression – A summary. Front Hum Neurosci. 2009 Sep 25;3:26. doi: 10.3389/neuro.09.026.2009. eCollection 2009.

20. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. J Affect Disord. 2011 Nov;134(1-3):20-31. doi: 10.1016/j.jad.2010.11.011. Epub 2010 Dec 15.

21. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. 224 p.

22. Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011 Aug;132 Suppl 1:S9-S13. doi: 10.1016/j.jad.2011.03.046. Epub 2011 Apr 22.

23. McDermott LM, Ebmeier KP. A metaanalysis of depression severity and cognitive function. J Affect Disord. 2009 Dec;119(1-3): 1-8. doi: 10.1016/j.jad.2009.04.022. Epub 2009 May 9.

24. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: Determinants, substrates, and treatment interventions. Depress Anxiety. 2013 Jun;30(6):515-27. doi: 10.1002/da.22063. Epub 2013 Mar 6.

25. Millan MJ, Agid Y, Brü ne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012 Feb 1;11(2):141-68. doi: 10.1038/nrd3628.

26. Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.). doi: 10.14412/2074-2711-2011-159

27. Mowla A, Ashkani H, Ghanizadeh A, et al. Do memory complaints represent impaired memory performance in patients with major depressive disorder? Depress Anxiety. 2008; 25(10):E92-6.

28. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: Impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry. 2008 Jun;165(6):731-9. doi: 10.1176/appi.ajp.2008.07040574. Epub 2008 Apr 1.

29. Rock PL, Roiser JP. Riedel WJ, Blackwell AD. Cognitive impairment in depression: A systematic review and meta-analysis. Psychol Med. 2014 Jul;44(10):2029-40. doi: 10.1017/S0033291713002535. Epub 2013 Oct 29.

30. Bora E, Harrison BJ, Yü cel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: A metaBanalysis. Psychol Med. 2013 Oct;43(10):2017-26. doi: 10.1017/S0033291712002085. Epub 2012 Oct 26.

31. Behnken A, Schöning S, Gerss J, et al. Persistent non-verbal memory impairment in remitted major depression – caused byencoding deficits? J Affect Disord. 2010 Apr;122(1-2): 144-8. doi: 10.1016/j.jad.2009.07.010. Epub 2009 Aug 18.

32. Airaksinen E, Wahlin A, Larsson M, Forsell Y. Cognitive and social functioning in recovery from depression: results from a population-based three -year follow-up. J Affect Disord. 2006 Nov;96(1-2):107-10. Epub 2006 Jun 19.

33. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl. 1998;393:6-11.

34. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med. 1998 Sep;28(5):1027-38.

35. Sibille E, French B. Biological substrates underpinning diagnosis of major depression. Int J Neuropsychopharmacol. 2013 Sep;16(8): 1893-909. doi: 10.1017/S1461145713000436. Epub 2013 May 14.

36. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressivedisorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013 May;18(5):595-606. doi: 10.1038/mp.2012.33. Epub 2012 Apr 24.

37. Kessing LV, Andersen PK. Evidence for clinical progression of unipolar and bipolar disorders. Acta Psychiatr Scand. 2017 Jan;135(1): 51-64. doi: 10.1111/acps.12667. Epub 2016 Nov 10.

38. Abas MA, Sahakian BJ, Levy R. Neuropsychological deficits and CT scan changes in elderly depressives. Psychol Med. 1990 Aug;20(3):507-20.

39. Gavrilova SI. Alzheimer's disease: current understanding of diagnosis and therapy. Russkii meditsinskii zhurnal. 1997;(20):7. (In Russ.).

40. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

41. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.

42. Miller LJ. The use of cognitive enhancers in behavioural disturbances of Alzheimer's disease. Consult Pharm. 2007 Sep;22(9):754-62.

43. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.

44. Gavrilova SI, Gerasimov NP, Kalyn YaB, et al. Long-term effects of glutamatergic therapy of Alzheimer's disease at the stage of moderately severe and severe dementia (results of a 26-week comparative clinical study in parallel groups of patients treated with acatinol memantine and receiving symptomatic neuroleptic therapy). Sotsial'naya i klinicheskaya psikhiatriya. 2006;16(1):32-7. (In Russ.).

45. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of oncedaily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.

46. Voznesenskaya TG, Medvedeva AV, Yakhno NN. Non-cognitive neuropsychiatric disorders in Alzheimer's disease and their correction. Nevrologicheskii zhurnal. 2010;15(4):18-25. (In Russ.).

47. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioural and psychological symptoms related to dementia – a systematic meta-analyses. Ann Pharmacother. 2008 Jan;42(1):32-8. Epub 2007 Dec 4.

48. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe AD by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 May;23(5):537-45.

49. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.

50. Fan P. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br J Pharmacol. 1994 Jul;112(3):741-4.

51. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8649-54. doi: 10.1073/pnas. 1323920111. Epub 2014 May 27.

52. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatin: meta-analysis of published and unpublished studies. BMJ. 2014 Mar 19;348: g1888. doi: 10.1136/bmj.g1888.

53. Khoo AL, Zhou HJ, Teng M. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs. 2015 Aug;29(8):695-712. doi: 10.1007/s40263-015-0267-6.

54. Kennedy SH, Avedisova A, BelaÏdi C, et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016 Feb;26(2):378-389. doi: 10.1016/j.euroneuro.2015.09.006. Epub 2015 Sep 25.

55. Llorka P, Gourion D. Course of anhedonia and depressive symptoms in a population of depressed outpatients treated with agomelatine. Eur Neuropsychopharmacol. 2014;24(Suppl 2): S468. doi: 10.1016/S0924-977X(14)70749-7.

56. Callegari I, Mattei C, Benassi F, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegener Dis. 2016;16(5-6):352-6. doi: 10.1159/000445873. Epub 2016 May 27.

57. Karaiskos D, Pappa E, Katirtzoglou E. Agomelatine for treating apathy in alzheimer's disease. Eur Neuropsychopharmacol. 2019; 29(Suppl 1):1.

58. Romanov DV, Volel' BA, Petelin DS. Approaches to therapy for depressions in neurology: prospects for the use of agomelatine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):101-10. (In Russ.). doi: 10.14412/2074-2711-2018-4-101-110

59. Kalyn YaB, Safarova TP, Yakovleva OB, et al. Experience of using valdoxan (agomelatin) in gerontopsychiatric hospital for the treatment of elderly patients with depression. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015; 115(11):55-62. (In Russ.).

60. Medvedev VE, Korovyakova EA, Frolova VI, Gushanskaya EV. Antidepressant therapy in patients with cardiovascular diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):131-40. (In Russ.). doi: 10.14412/2074-2711-2019-1131-140.


For citation:


Tyuvina N.A., Prokhorova S.V., Maksimova T.N., Verbitskaya M.S. Cognitive impairment in depression and Alzheimer's disease: differential diagnosis and approaches to therapy. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):116-123. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3-116-123

Views: 25


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)